Arvinas, Inc.ARVN
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing targeted protein degradation therapies, a novel approach to treating diseases by harnessing the body's own protein disposal system. Its lead programs focus on oncology, including ARV-471 for breast cancer and ARV-110 for prostate cancer, with early clinical data generating significant investor interest. The company's platform and pipeline make it a key name to watch in the emerging field of PROTAC-based therapeutics.
Congressional Interest in Arvinas, Inc. (ARVN)
1 member of Congress has disclosed 1 trade in Arvinas, Inc. (ARVN), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Who in Congress Is Trading ARVN?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2015-10-05 | KENNY MARCHANT | buy | $15K-$50K |